Inventor · disambiguated record
Anthony Boitano
Also filed as: BOITANO ANTHONY · BOITANO ANTHONY E · BOITANO ANTHONY EDWARD
19 granted patents·43 pending applications·59 citations·filing 2009–2024
92Inventor score
Files withMAGENTA THERAPEUTICS INC38NOVARTIS AG8HEIDELBERG PHARMA RES GMBH4VOR BIOPHARMA INC3BOITANO ANTHONY E2
Top patents by PatentIndex Score
62 records- 0192US10899843B2Compositions and methods for the depletion of CD117+ cellsMAGENTA THERAPEUTICS INC·Filed 2018·Granted Jan 26, 2021·8 cites·38 claims
- 0291US10882915B2Compositions and methods for the depletion of CD117+ cellsMAGENTA THERAPEUTICS INC·Filed 2018·Granted Jan 5, 2021·9 cites·27 claims
- 0389US11572411B2Anti-CD117 antibodies and conjugatesMAGENTA THERAPEUTICS INC·Filed 2020·Granted Feb 7, 2023·2 cites·14 claims
- 0489US9580426B2Compounds that expand hematopoietic stem cellsBOITANO ANTHONY E·Filed 2013·Granted Feb 28, 2017·13 cites·20 claims
- 0588US12171839B2Antibody drug conjugates for ablating hematopoietic stem cellsNOVARTIS AG·Filed 2022·Granted Dec 24, 2024·1 cites·11 claims
- 0688US8927281B2Method for expanding hematopoietic stem cellsBOITANO ANTHONY E·Filed 2009·Granted Jan 6, 2015·11 cites·22 claims
- 0786US10058573B1Dosing regimens for the mobilization of hematopoietic stem cellsMAGENTA THERAPEUTICS INC·Filed 2017·Granted Aug 28, 2018·7 cites·9 claims
- 0885US12251448B2Compositions and methods for the depletion of CD5+ cellsHEIDELBERG PHARMA RES GMBH·Filed 2021·Granted Mar 18, 2025·1 cites·13 claims
- 0984US11958908B2Compositions and methods for the depletion of CD117+ cellsCRISPR THERAPEUTICS AG·Filed 2020·Granted Apr 16, 2024·1 cites·26 claims
- 1080US12403200B2Methods and compositions for treating autoimmune diseasesVOR BIOPHARMA INC·Filed 2021·Granted Sep 2, 2025·1 cites·24 claims
- 1179US10434185B2Compositions and methods for the depletion of CD137+ cellsMAGENTA THERAPEUTICS INC·Filed 2018·Granted Oct 8, 2019·1 cites·29 claims
- 1279US2025064964A1Antibody drug conjugates for ablating hematopoietic stem cellsNOVARTIS AG·Filed 2024·Application pending·0 cites
- 1379US2025295698A1Dosing regimens for the mobilization of hematopoietic stem cellsENSOMA INC·Filed 2024·Application pending·0 cites
- 1478US2024360238A1Compositions and methods for the depletion of cd117+ cellsCRISPR THERAPEUTICS AG·Filed 2024·Application pending·0 cites
- 1577US11260079B2Dosing regimens for the mobilization of hematopoietic stem and progenitor cellsMAGENTA THERAPEUTICS INC·Filed 2019·Granted Mar 1, 2022·1 cites·23 claims
- 1677US9834755B2Compositions and methods for enhanced generation of hematopoietic stem/progenitor cellsHUTCHINSON FRED CANCER RES·Filed 2012·Granted Dec 5, 2017·2 cites·22 claims
- 1777US2025082767A1Compositions and methods for the depletion of cd5+ cellsHEIDELBERG PHARMA RES GMBH·Filed 2024·Application pending·0 cites
- 1876US12209135B2Anti-CD45 antibodies and conjugates thereofVOR BIOPHARMA INC·Filed 2024·Granted Jan 28, 2025·0 cites·22 claims
- 1975US10576161B2Compositions and methods for the depletion of CD137+ cellsMAGENTA THERAPEUTICS INC·Filed 2018·Granted Mar 3, 2020·1 cites·24 claims
- 2073US2025032549A1Dosing regimens for the mobilization of hematopoietic stem and progenitor cellsENSOMA INC·Filed 2024·Application pending·0 cites
- 2172US2023130646A1Dosing regimens for the mobilization of hematopoietic stem cellsMAGENTA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2270US2021187033A1Compounds that expand hematopoietic stem cellsNOVARTIS AG·Filed 2020·Application pending·0 cites
- 2366US2024002843A1Compositions and methods for the treatment of hemoglobinopathiesNOVARTIS AG·Filed 2022·Application pending·0 cites
- 2466US2024075157A1Fc silenced antibody drug conjugates (adcs) and uses thereofMAGENTA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2563US2022096559A1Dosing regimens for the mobilization of hematopoietic stem and progenitor cellsMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2660US2020276326A1Compositions and methods for the depletion of cd5+ cellsMAGENTA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2760US2019336536A1Dosing regimens for the mobilization of hematopoietic stem and progenitor cellsMAGENTA THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2859US2020289664A1Compositions and methods for the depletion of cd137+ cellsMAGENTA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2957US11357864B2Antibody drug conjugates for ablating hematopoietic stem cellsNOVARTIS AG·Filed 2017·Granted Jun 14, 2022·0 cites·23 claims
- 3056US2023330185A1Methods and compositions for transducing hematopoietic stem and progenitor cells in vivoMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3156US2019167726A1Dosing Regimens for the Mobilization of Hematopoietic Stem CellsMAGENTA THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3256US2021283267A1Therapeutic methods using antibody drug conjugates (adcs)MAGENTA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3356US2022177578A1Anti-cd117 antibodies and uses thereofMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3456US2022177575A1Anti-cd117 antibodies and uses thereofMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3556US2017239296A1Compounds that expand hematopoietic stem cellsNOVARTIS AG·Filed 2017·Application pending·0 cites
- 3656US2022175946A1Conditioning methods for gene therapyMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3755US12006370B2Use of anti-CD5 antibody drug conjugate (ADC) in allogeneic cell therapyHEIDELBERG PHARMA RES GMBH·Filed 2021·Granted Jun 11, 2024·0 cites·30 claims
- 3854US12403185B2Use of anti-CD137 antibody drug conjugate (ADC) in allogeneic cell therapyHEIDELBERG PHARMA RES GMBH·Filed 2021·Granted Sep 2, 2025·0 cites·23 claims
- 3954US2020376135A1Fc silenced antibody drug conjugates (adcs) and uses thereofMAGENTA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4053US12291576B2Anti-CD45 antibodies and conjugates thereofVOR BIOPHARMA INC·Filed 2021·Granted May 6, 2025·0 cites·26 claims
- 4153US2022249683A1T-cell depleting therapiesMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4253US2022175944A1Anti-cd117 antibody-drug conjugates and uses thereofMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4353US2021260212A1Use of an anti-cd2 antibody drug conjugate (adc) in allogeneic cell therapyMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4453US2021379033A1Methods of treating cancer with aryl hydrocarbon receptor antagonistsMAGENTA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4552US2022226493A1Anthracycline antibody-drug conjugates and uses thereofMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4652US2023390412A1Compositions and methods for allogeneic transplantationMAGENTA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4752US2021095039A1Anti-cd252 antibodies, conjugates, and methods of useMAGENTA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4852US2018142212A1Compositions and methods for enhanced generation of hematopoietic stem/progenitor cellsHUTCHINSON FRED CANCER RES·Filed 2017·Application pending·0 cites
- 4952US2022401481A1Dosing regimens for the mobilization of hematopoietic stem and progenitor cellsMAGENTA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 5051US2022175951A1Anti-CD45 Antibody Drug Conjugates and Uses ThereofMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
Showing the top 50 of 62 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →